On Tuesday, Bolt Biotherapeutics Inc (NASDAQ: BOLT) was -4.02% drop from the session before settling in for the closing price of $0.44. A 52-week range for BOLT has been $0.38 – $1.56.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 168.54%. When this article was written, the company’s average yearly earnings per share was at 28.79%. With a float of $25.20 million, this company’s outstanding shares have now reached $38.34 million.
Let’s determine the extent of company efficiency that accounts for 52 employees. In terms of profitability, gross margin is -67.58%, operating margin of -776.13%, and the pretax margin is -665.56%.
Bolt Biotherapeutics Inc (BOLT) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Bolt Biotherapeutics Inc stocks. The insider ownership of Bolt Biotherapeutics Inc is 34.17%, while institutional ownership is 20.02%.
Bolt Biotherapeutics Inc (BOLT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.73% during the next five years compared to -13.73% drop over the previous five years of trading.
Bolt Biotherapeutics Inc (NASDAQ: BOLT) Trading Performance Indicators
You can see what Bolt Biotherapeutics Inc (BOLT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.65, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -0.63 in one year’s time.
Technical Analysis of Bolt Biotherapeutics Inc (BOLT)
Looking closely at Bolt Biotherapeutics Inc (NASDAQ: BOLT), its last 5-days average volume was 0.17 million, which is a jump from its year-to-date volume of 0.13 million. As of the previous 9 days, the stock’s Stochastic %D was 72.98%. Additionally, its Average True Range was 0.04.
During the past 100 days, Bolt Biotherapeutics Inc’s (BOLT) raw stochastic average was set at 12.34%, which indicates a significant decrease from 37.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.29% in the past 14 days, which was lower than the 52.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4733, while its 200-day Moving Average is $0.6095. However, in the short run, Bolt Biotherapeutics Inc’s stock first resistance to watch stands at $0.4638. Second resistance stands at $0.5077. The third major resistance level sits at $0.5323. If the price goes on to break the first support level at $0.3953, it is likely to go to the next support level at $0.3707. Should the price break the second support level, the third support level stands at $0.3268.
Bolt Biotherapeutics Inc (NASDAQ: BOLT) Key Stats
There are 38,273K outstanding shares of the company, which has a market capitalization of 16.10 million. As of now, sales total 7,880 K while income totals -69,200 K. Its latest quarter income was 1,140 K while its last quarter net income were -15,180 K.
